Plasma PCSK9 Levels Are Positively Correlated With LDL-Cholesterol Concentrations in Familial Hypercholesterolemia

被引：0
|
作者：
Drouin-Chartier, Jean-Philippe
Tremblay, Andre J.
Hogue, Jean-Charles
Ooi, Teik C.
Lamarche, Benoit
Couture, Patrick
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A427
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [2] PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. John Betteridge
    [J]. Nature Reviews Endocrinology, 2013, 9 : 76 - 78
  • [3] The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
    Piper, Derek E.
    Jackson, Simon
    Liu, Qiang
    Romanow, William G.
    Shetterly, Susan
    Thibault, Stephen T.
    Shan, Bei
    Walker, Nigel P. C.
    [J]. STRUCTURE, 2007, 15 (05) : 545 - 552
  • [4] Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
    Huijgen, R.
    Fouchier, S. W.
    Denoun, M.
    Hutten, B. A.
    Vissers, M. N.
    Lambert, G.
    Kastelein, J. J. P.
    [J]. JOURNAL OF LIPID RESEARCH, 2012, 53 (05) : 979 - 983
  • [5] RELATIONSHIP BETWEEN PLASMA PCSK9 AND LDL LEVELS IN FAMILIAL HYPERCHOLESTEROLEMIA (FH) AND HYPOBETALIPOPROTEINEMIA (FHBL)
    Lambert, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [6] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    [J]. ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [7] Adenoviral mediated overexpression of the subtilisin protease Pcsk9 increases plasma LDL-cholesterol levels in the mouse
    Maxwell, KN
    Drazul-Schrader, D
    Rothblat, GH
    Breslow, JL
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) : E1 - E1
  • [8] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [9] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [10] Evolocumab (Repatha) A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 139 - 140
12345